Tag: PCI

Stephan Windecker presents preferred strategies with Apixaban

TCT 2019: Apixaban plus a P2Y12 inhibitor is the optimal strategy...

A prespecified analysis of data from the AUGUSTUS study, released at late-breaking session at the Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019; 25–29 September,...

ESC 2017: Case builds for dropping aspirin from triple therapy in...

The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor...

AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients...

Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily dose of the drug and a P2Y12 inhibitor and...